FK317: A novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 1, 1998, Pages 31-36

  Naoe, Yoshinori ^a   Inami, Masamichi ^a   Matsumoto, Sanae ^a   Nishigaki, Fusako ^a   Tsujimoto, Susumu ^a   Kawamura, Ikuo ^a   Miyayasu, Kikuo ^a   Manda, Toshitaka ^a   Shimomura, Kyoichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antitumor effect; FK317; FK973; MMC; Vascular leak syndrome

Indexed keywords

1 ACETYL 8 CARBAMOYLOXYMETHYL 3,9 EPOXY 5 FORMYL 1A,2,3,8,9,9A HEXAHYDRO 9 HYDROXY 7 METHOXY 1H AZIRINO[2,3 C][1]BENZAZOCINE ACETATE; 1 ACETYL 8ALPHA (CARBAMOYLOXYMETHYL) 3,9 EPOXY 5 FORMYL 1,1A,2,8,9,9A OCTAHYDROAZIRINO[2,3 C][1]BENZAZOCINE 7,9 DIOL ACETATE; ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY LEAK SYNDROME; CELL LINE; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL LINE; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; RAT; SOLID TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY LEAK SYNDROME; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MALE; MICE; MICE, INBRED STRAINS; MITOMYCIN; NEOPLASMS, EXPERIMENTAL; OXAZINES; PLEURAL EFFUSION; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED;

EID: 0031979227     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050781     Document Type: Article

References (19)

1. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphoma resistant to conventional therapy. Blood 82: 2624
2. Brandt SJ, Peter WP, Atwater SK (1988) Effect of human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318: 869
3. Driscoll JS (1984) The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep 68: 63
4. Goldin A, Venditti JM, MacDonald JS, Muggia FM, Henney JE, Devita JT Jr (1981) Current results of the screening program at the division of cancer treatment. National Cancer Institute. Eur J Cancer 17: 129
5. Gorin NC, Coiffier B, Hayat M, Fouillard L, Kuentz M, Flesch M, Colombat P, Boivin P, Slavin S, Philip T (1992) Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 80: 1149
6. Iwami M, Kiyoto S, Terano H, Kohsaka M, Aoki H, Imanaka H (1987) A new antitumor antibiotic, FR-900482 (I). Taxonomic studies on the producing strain: a new species of genus Streptomyces. J Antibiot (Tokyo) 40: 589
7. Kiyoto S, Shibata T, Yamashita M, Komori T, Okuhara M, Terano H, Kohsaka M, Aoki H (1987) A new antitumor antibiotic, FR-900482 (II). Production, isolation, characterization and biological activity. J Antibiot (Tokyo) 40: 594
8. Majima H, Hasegawa K, Fukuoka M, Furuse K, Wakui A, Furue H (1990) Phase I clinical and pharmacokinetic study of FK973. Proc Am Soc Clin Oncol 9: 78
9. Parkinson DR (1988) Interleukin-2 in cancer therapy. Semin Oncol 15: 10
10. Pazdur R, Ho DH, Daugherty K, Bradner WT, Krakoff IH, Raber MN (1991) Phase I trial of FK973: description of a delayed vascular leak syndrome. Invest New Drugs 9: 337
11. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shilioni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313: 1485
12. Rosenberg SA, Lotze MT, Muul LM, Chang AE. Aviis FP, Leitman S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White D (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889
13. Shimomura K, Hirai O, Mizota T, Matsumoto S, Mori J, Shibayama F, Kikuchi H (1987) A new antitumor antibiotic, FR-900482 (III). Antitumor activity in transplantable experimental tumors. J Antibiot (Tokyo) 40: 600
14. Shimomura K, Manda T, Mukumoto S, Masuda K, Nakamura T, Mizota T, Matsumoto S, Nishigaki F, Oku T, Mon J, Shibayama F (1988) Antitumor activity and hematotoxicity of a new, substituted dihydro-benzoxazine, FK973, in mice. Cancer Res 48: 1166
15. Siegall CB, Liggitt D, Chace D, Topper MA, Fell P (1994) Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proe Natl Aead Sci USA 91: 9514
16. Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9: 694
17. Staquet MJ, Byar DP, Green SB, Rozencweig M (1983) Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep 67: 753
18. Staquet MJ, Byar DP, Green SB, Rozencweig M (1985) Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: reply to a commentary. Cancer Treat Rep 69: 13391
19. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Gheti V, Uhr JW, Thorpe PE (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51: 4052